SNMMI, International Atomic Energy Agency combine forces on nuke-med education

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is partnering with the International Atomic Energy Agency (IAEA) to beef up educational resources for health professionals wherever in the world they may be.

The two groups jointly announced their agreement Oct. 23.

One of the primary ways parties interested in molecular imaging and/or nuke med will access materials—for free—is online, through IAEA’s existing Human Health Campus.

The agreement includes a plan to develop new materials for the website, which IAEA says is already drawing upwards of 5,000 visitors per month.

“We are witnessing a growing demand for nuclear medicine services to manage an increasing number of patients suffering from non-communicable diseases, such as cancer,” Diana Paez, MD, head of the IAEA’s nuclear medicine and diagnostic Imaging section, says in the announcement.

SNMMI president Bennett Greenspan, MD, adds that broadening access to learning materials covering both diagnostic and therapeutic subjects “will strengthen the knowledge of professionals and enhance patient care.”

The education-focused collaboration builds on a working relationship between the two groups that began in 2012. Since then, around 600 people from Asia and Latin America have benefited from training opportunities in PET/CT, according to the announcement.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care. 

After three years of intermittent shortages of nuclear imaging tracer technetium-99m pyrophosphate, there are no signs of the shortage abating.